Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens

Naoe Goto, Hisashi Tsurumi, Senji Kasahara, Nobuhiro Kanemura, Takeshi Hara, Ichiro Yasuda, Masahito Shimizu, Nobuo Murakami, Michio Sawada, Toshiki Yamada, Masao Takemura, Mitsuru Seishima, Yusuke Kito, Tsuyoshi Takami, Hisataka Moriwaki

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)

Abstract

Background: We have previously reported that serum interleukin-18 (IL-18) concentration predicted the clinical outcome of patients with aggressive non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). When rituximab (R) was added to this regimen, the prognosis of diffuse large B-cell lymphoma (DLBCL) was markedly improved. Patients and Methods: In this study, we re-evaluated the prognostic significance of serum IL-18 in 227 DLBCL patients. Seventy-three patients received CHOP before R-era, and 154 patients received rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) recently. Result: Four-year overall survival (4-yr OS) rates for patients in CHOP group with IL-18≥720pg/mL and <720pg/mL were 8.2% and 67.3% (P<0.0001), respectively, and 4-yr OS rates with IL-18≥590 and <590pg/mL in R-CHOP group were 53.4% and 77.8% (P=0.0008), respectively. Multivariate analysis revealed that serum IL-18 correlated most significantly with OS and progression-free survival (PFS) in both groups (OS: P<0.0001, PFS: P<0.0001, in CHOP group; OS: P=0.0147, PFS: P=0.0084 in R-CHOP group). The high serum IL-18 patients with poor prognostic group in revised IPI or with non-germinal center B-cell phenotype had a very poor prognosis. Conclusion: Serum IL-18 might be a powerful prognostic factor for DLBCL in R-era.

Original languageEnglish
Pages (from-to)217-227
Number of pages11
JournalEuropean Journal of Haematology
Volume87
Issue number3
DOIs
Publication statusPublished - 09-2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint

Dive into the research topics of 'Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens'. Together they form a unique fingerprint.

Cite this